Saturday, May 31, 2003
Conference Attendees at ASCO 2003
A Phase II Study of Docetaxel and Carboplatin as Neoadjuvant Therapy for Patients with Early T and Advanced N Stage Nasopharyngeal Carcinoma(NPC) Age-Specific Sub-Analysis of ECOG 1594: Fit Elderly Patients (70-80 yrs) with Non-Small Cell Lung Cancer Do As Well As Younger Patients (<70 yrs) Can biochemical failure (ASTRO definition) be used as a surrogate endpoint for prostate cancer survival in phase III localized prostate cancer clinical trials? Analysis of RTOG protocol 92-02 Chemohormonal therapy in premenopausal node-positive, receptor positive breast cancer: An Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT 0101) Natural history of progression of patients with biochemical (PSA) relapse following radical prostatectomy: Update Older women with node positive (N+) breast cancer (BC) get similar benefits from adjuvant chemotherapy (adj) as younger patients (pts): The Cancer and Leukemia Group B (CALGB) experience P53, EGFR, and PTEN as markers of diagnosis and prognosis in patients with anaplastic glioma enrolled in NCCTG clinical trials Paclitaxel (T) following doxorubicin/cyclophosphamide(AC) as adjuvant chemotherapy for node positive breast cancer: Results from NSABP B-28 Phase III trial of androgen suppression adjuvant to definitive radiotherapy. Long term results of RTOG study 85-31. Pulmonary radiological-, physiological-, and clinical side-effects after adjuvant radiotherapy in breast cancer Randomized Phase III Study of I.V. Vinorelbine plus hormonotherapy versus hormonotherapy alone in hormone refractory prostate cancer (HRPC) Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy The role of hormonal treatment for biochemical recurrence in patients following radical prostatectomy Treatment of Elderly Non-Small Lung Cancer (NSCLC) Patients with 3 Different Schedules of Weekly Paclitaxel in Combination with Carboplatin: Subanalysis of a Randomized Trial Two year survival for Concurrent Carboplatin, Paclitaxel, and Hyperfractionated Radiotherapy in Unresectable Head and Neck Cancer. Vital statistics following surgery or radiation for patients with clinically localized prostate cancer managed during the PSA era.